Tolevamer, an orally administered, toxin-binding polymer for Clostridium difficile-associated diarrhea.

Abstract

Genzyme Corp is developing tolevamer, an anionic toxin-binding polymer that binds and neutralizes the Clostridium difficile A and B toxins, for the potential treatment of C difficile-associated diarrhea (CDAD). Two phase III clinical trials of tolevamer in patients with CDAD have been completed and results from the second trial are expected to be released imminently.

• Authors: Noah Scheinfeld, Kristen Biggers
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 9 Issue 8 Pg. 913-24 (Aug 2008) ISSN: 1472-4472 [Print] England
• PMID: 18666039 (Publication Type: Journal Article, Review)

Chemical References

• Anti-Bacterial Agents
• Polymers
• Sulfonic Acids
• styrenesulfonic acid polymer

Topics

• Administration, Oral
• Animals
• Anti-Bacterial Agents (administration & dosage, pharmacokinetics)
• Clinical Trials as Topic
• Clostridioides difficile (drug effects)
• Contraindications
• Drug Evaluation, Preclinical
• Enterocolitis, Pseudomembranous (drug therapy, physiopathology)
• Humans
• Patents as Topic
• Polymers (administration & dosage, pharmacokinetics)
• Sulfonic Acids